The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling | Synapse
January 12, 2024Open Access
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Our research findings strongly suggest that CD155/TIGIT represents a promising therapeutic target for treating TNBC.